|
|
Actinium Pharmaceuticals and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
"Actinium has amassed extensive clinical experience, technical know-how and research capabilities for the development of next-generation targeted radiotherapies that we are excited to bring to this collaboration with AVEO, which has a portfolio of high-affinity antibodies and is currently commercializing FOTIVDA (tivozanib) in advanced RCC. We believe ErbB3 is a validated and differentiated target that is aptly suited for radio-conjugate development. Using our AWE platform, we will harness the powerful Ac-225 payload to enhance targeted cell killing against a target that is overexpressed in a number of cancers that are difficult to treat with traditional oncology therapies. A member of the epidermal growth factor family of receptors, ErbB3 has been gaining increasing recognition as a validated targeted, we are committed to rapidly advance and evaluate this novel Ac-225 ErbB3 targeted radiotherapy together with AVEO," said Sandesh Seth, Chairman and CEO of Actinium.
|
|
Career Event
|
|
Industry Careers for PhDs – Panel Discussion and Networking Events on March 9 and 15 for R&D and Non-Bench Jobs
Register here for Wednesday, March 9, 5:00-6:30pm EST – Zoom event on Drug Discovery Research Careers
Register here for Tuesday, March 15, 5:00-6:30pm EST – Zoom event on Drug Discovery Non-Bench Careers
Register for one or both sessions!
All Eventbrite registrants will receive the Zoom meeting link via email on the day of the event.
Are you a PhD student or postdoc interested in learning more about industry career options, both bench and non-bench?
Attend 2 Zoom panel discussion and networking events hosted by the MSKCC Office of Career and Professional Development, STEMPeers, and INet NYC, as part of our 3rd annual event on launching an industry career!
On March 9, 5:00-6:30pm EST, you will meet with 7 scientists working in various types of therapeutic development (small molecule, cell, gene), as well as medicinal chemistry, AI and data science, and CMC.
On March 15, 5:00-6:30pm EST, you will meet with 6 industry professionals who have transitioned into various non-bench roles, including clinical research, business development, medical science liaison and medical affairs, medical communications, and regulatory/QC.
|
|
Disclaimer
The editors take care to share authentic information. In case of any discrepancies please write to medness.newsletter@gmail.com
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Medness. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for Medness. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
|
|
|
|
|
|
|